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Background: Most psoriasis patients have mild to moderate disease, commonly treated topically. Current topical
agents have limited efficacy and undesirable side effects associated with long-term use. Tofacitinib is a small
molecule Janus kinase inhibitor investigated for the topical treatment of psoriasis.
Methods: This was a 12-week, randomized, double-blind, parallel-group, vehicle-controlled Phase 2b study of
tofacitinib ointment (2 % and 1 %) applied once (QD) or twice (BID) daily in adults with mild to moderate plaque
psoriasis. Primary endpoint: proportion of patients with Calculated Physician’s Global Assessment (PGA-C) clear or
almost clear and ≥2 grade improvement from baseline at Weeks 8 and 12. Secondary endpoints: proportion of
patients with PGA-C clear or almost clear; proportion achieving Psoriasis Area and Severity Index 75 (PASI75)
response; percent change from baseline in PASI and body surface area; change from baseline in Itch Severity Item
(ISI). Adverse events (AEs) were monitored and clinical laboratory parameters measured.
Results: Overall, 435 patients were randomized and 430 patients received treatment. The proportion of patients
with PGA-C clear or almost clear and ≥2 grade improvement from baseline at Week 8 was 18.6 % for 2 %
tofacitinib QD (80 % confidence interval [CI] for difference from vehicle: 3.8, 18.2 %) and 22.5 % for 2 % tofacitinib
BID (80 % CI: 3.1, 18.5 %); this was significantly higher vs vehicle for both dosage regimens. No significant difference
vs vehicle was seen at Week 12. Significantly more patients achieved PGA-C clear or almost clear with 2 %
tofacitinib QD and BID and 1 % tofacitinib QD (not BID) at Week 8, and with 2 % tofacitinib BID at Week 12. Pruritus
was significantly reduced vs vehicle with 2 % and 1 % tofacitinib BID (starting Day 2), and 2 % tofacitinib QD (starting
Day 3). Overall, 44.2 % of patients experienced AEs, 8.1 % experienced application site AEs, and 2.3 % experienced
serious AEs. The highest incidence of AEs (including application site AEs) was in the vehicle QD group.
Conclusions: In adults with mild to moderate plaque psoriasis, 2 % tofacitinib ointment QD and BID showed greater
efficacy than vehicle at Week 8, but not Week 12, with an acceptable safety and local tolerability profile.
Trial registration: NCT01831466 registered March 28, 2013.
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The World Health Organization has described psoriasis
as a ‘chronic, non-communicable, painful, disfiguring
and disabling disease for which there is no cure’ [1]. The
majority of people with plaque psoriasis (75–90 %) are
considered to have relatively limited mild to moderate
disease [2, 3]. Many treatments are available for mild to
moderate psoriasis, including topical treatment with cor-
ticosteroids, often in combination with vitamin D
analogues [4–6]. The use of mid to high potency cortico-
steroids can be limited by local and systemic adverse
effects, particularly on the face and intertriginous areas
[5, 7, 8]. Irritation or burning can also occur with vita-
min D analogues [9–11]. Topical therapy is also used in
combination with phototherapy or systemic therapy in
patients with moderate to severe psoriasis [12].
A substantial proportion of patients with psoriasis are
dissatisfied with their current treatment [13]. The lim-
ited efficacy of non-steroidal topical monotherapy or low
potency corticosteroids and the safety issues associated
with long-term use of mid to high potency topical corti-
costeroids suggest an unmet need exists for additional
topical therapeutic options.
Tofacitinib (CP-690,550) is a small molecule Janus
kinase (JAK) inhibitor; inhibition of JAK1 and JAK3 by
tofacitinib blocks signaling of multiple cytokines impli-
cated in immune response and inflammation. The oral
formulation of tofacitinib is effective in patients with
moderate to severe plaque psoriasis [14–16]. An oint-
ment formulation of tofacitinib investigated for the topical
treatment of psoriasis in a Phase 2a study showed the
ointment (2 % twice daily [BID]) was effective with accept-
able tolerability for mild to moderate psoriasis [17].
The primary objective of this Phase 2b study was to
further characterize the efficacy and safety of tofacitinib
ointment (2 % and 1 %) applied once daily (QD) or BID
over 12 weeks in adult patients with mild or moderate
chronic plaque psoriasis, compared with the corresponding
vehicle.
Methods
Study design and treatment
This randomized, double-blind, parallel-group, vehicle-
controlled study (NCT01831466), conducted at 52 cen-
ters in the United States, Canada, Denmark, and Poland,
was initiated in May 2013 and completed in September
2014. Patients were randomized 1:1:1 to receive 1 %
(10 mg/g) tofacitinib ointment, 2 % (20 mg/g) tofacitinib
ointment or corresponding vehicle. Randomization was
stratified by baseline severity of psoriasis as defined by
the Calculated Physician’s Global Assessment (PGA-C).
Investigators, study staff and sponsor remained blinded
to treatment and randomization information until after
the conclusion of the study. Investigator sites wereassigned to either QD or BID regimen, but not both;
neither investigators nor patients were blinded to
regimen.
Tofacitinib ointment was provided in 60 g tubes at a
strength of 2 % (maximum feasible concentration) and
1 %; the matching vehicle contained the same inactive
ingredients as tofacitinib ointment. Treatments were
administered topically at a target application coverage of
3 mg/cm2 to a treatment area corresponding to 2 to
20 % of the patient’s body surface area (BSA). Patients
were instructed to treat all treatment-eligible psoriatic
areas identified at baseline for 12 weeks, regardless of
clearing or improvement in psoriasis. On study visit
days, showering or bathing, but not moisturizing, was
permitted prior to attending, and study drug was applied
in the clinic after study assessments were completed.
After the final study treatment, the treatment areas were
left untreated during the 4-week follow-up period.
Use of shampoo containing tar, salicylic acid or low or
least potent corticosteroid products (eg hydrocortisone
and hydrocortisone acetate ≤1 %) was permitted on hair-
bearing scalp only throughout the study. The proprietary
ointment formulation contained standard excipients for
a topical formulation.Patients
Key inclusion criteria
Subjects were aged ≥18 years with chronic plaque
psoriasis for ≥6 months, were required to have a
PGA-C score of mild (2) or moderate (3), and have
plaque psoriasis covering 2–20 % of their BSA on the
trunk and/or limbs, with ≥1 % BSA involvement on
the trunk and/or limbs (excluding palms, soles,
elbows, knees and below the knees).Key exclusion criteria
Exclusion criteria included non-plaque forms of psoria-
sis; drug-induced psoriasis; evidence of skin conditions
that would interfere with the evaluation of psoriasis;
history of infection requiring hospitalization or treat-
ment with oral or topical antimicrobial therapy within
2 weeks prior to baseline; hepatitis B/C or HIV infection;
history of lymphoproliferative disorder or malignancy,
except adequately treated or excised basal/squamous cell
carcinoma, or cervical carcinoma in situ; evidence of
tuberculosis infection; treatment with ustekinumab
within the previous 4 months or other biologic agents
(excluding etanercept) within the previous 2 months;
phototherapy or treatment with etanercept or conven-
tional systemic treatments that could affect psoriasis,
such as oral or injectable corticosteroids, retinoids,
methotrexate, and cyclosporine, within 4 weeks prior to
the first study dose.
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costeroids, tars, keratolytics, anthralin, vitamin D
analogues, and retinoids) were discontinued for ≥2 weeks
prior to the first study dose.Assessments
Clinical signs of plaque psoriasis (erythema, induration
and scaling) were scored separately according to a 5-point
severity scale: clear (0), almost clear (1), mild (2), moder-
ate (3), and severe (4). These PGA subscores were then
summed, averaged, and rounded to the nearest whole
number to determine the PGA-C score and category [18].
Evaluation of the PGA-C excluded the scalp (even if the
hairless scalp was being treated with study drug), palms,
soles, and nails.
The primary endpoint was the proportion of subjects
achieving a PGA-C response of clear (0) or almost clear
(1) with ≥2 grade improvement from baseline at Week 8
and Week 12, independently. Secondary endpoints in-
cluded Week 8 and Week 12 assessments of the propor-
tion of patients achieving a PGA-C response of clear (0)
or almost clear (1); the proportion of patients achieving
a ≥75 % improvement from baseline in Psoriasis Area
and Severity Index (PASI75); the percent change from
baseline in PASI; and the percent change from baseline
in affected BSA.
Evaluation of patient-reported outcomes included change
from baseline in itch severity and in the Dermatology Life
Quality Index (DLQI). The severity of itch was assessed via
the Itch Severity Item (ISI), a single item instrument in
which the patient records itching over the previous 24 h on
a numerical rating scale of 0 (no itching) to 10 (worst
possible itching) [19]. ISI was recorded in the clinic during
Visit 1 (baseline/Day 1) and at Visits 3–7 (Weeks 2, 4, 8,
12, and 16), as well as once per day between Visit 1 and the
day before Visit 3 by the patient in a diary prior to applica-
tion of study treatment. Patients in the BID treatment
group recorded the ISI before applying either the morning
or evening treatment, but at the same time throughout this
period.
Safety endpoints included the incidence of treatment-
emergent adverse events (AEs), serious AEs (SAEs), and
application site AEs, plus the proportion of patients who
discontinued due to application site AEs. Physical exam-
ination, monitoring of vital signs, and clinical laboratory
assessments (including hematology, fasting serum chem-
istry, fasting lipid panels, and urinalysis) were
performed.
Pharmacokinetic (PK) endpoints included tofacitinib
PK concentrations for pre-dose and post-dose samples.
Pre-dose blood samples were collected at baseline and at
Weeks 2, 4, 8, and 12 (0 h). At selected sites, three PK
samples were also collected at Week 4 post-dosebetween 30 min and 1 h, between 2 and 3 h, and be-
tween 4 and 10 h.
Statistical analysis
This was an estimation study. A sample size of 70 sub-
jects per treatment group was selected, such that the
80 % confidence interval (CI) width of the difference
between tofacitinib and vehicle was approximately 19 %,
assuming a 21 % vehicle response and a 36 % response
in tofacitinib. Additionally, this sample size would yield
approximately 76 % power to establish the superiority of
each strength and regimen of tofacitinib to its respective
vehicle for the primary endpoint at the 0.10 (one-sided)
significance level. No adjustment for multiple compari-
sons was made.
Patients with mild or moderate psoriasis at baseline
(as defined by PGA-C) who were randomized and re-
ceived at least one dose of study medication (tofacitinib
or vehicle) were included in the analyses. Data at Week 8
and Week 12 were evaluated separately.
For the primary endpoint, standard error (SE) and
two-sided 80 % CI were calculated using the normal
approximation to the binomial proportions. A strati-
fied analysis was conducted by summarizing the
difference in proportions adjusted for the baseline
PGA-C disease severity using the Cochran-Mantel-
Haenszel approach [20, 21]. Patients with missing
values were considered non-responders.
PASI75 and PGA-C response of clear or almost clear
were analyzed using a marginal logistic regression model
fit by pseudo-likelihood (generalized linear mixed model
for repeated measures). Response proportions were esti-
mated from the model and odds ratios for treatment
contrasts along with 80 % CI were determined. Continu-
ous variables (eg percent change from baseline in PASI
and BSA, and change from baseline in ISI) were ana-
lyzed using a linear mixed model for repeated measures.
Least squares mean (LSM), difference in LSM, SE, and
two-sided 80 % CI were calculated. All analyses used
observed data without imputation. Separate models were
fit for the QD and BID data.
For comparisons in response proportions between the
active treatment and corresponding vehicle, statistical
significance was declared if the lower limit of the two-
sided 80 % CI for the response difference was >0 for the
primary efficacy endpoint, and if the lower limit of the
two-sided 80 % CI for the odds ratio was >1 for the sec-
ondary PGA-C and PASI75 endpoints. For comparisons
in LSMs between active treatment and corresponding
vehicle, statistical significance was declared if the upper
limit of the two-sided 80 % CI was <0 for percent
change from baseline in PASI and BSA and change from
baseline in ISI. No adjustment for multiple comparisons
was made.
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Software [22].Results
Patients
Overall, 435 patients were randomized (Fig. 1). In the
QD treatment groups, 218 patients received either 2 %
tofacitinib, 1 % tofacitinib, or vehicle (n = 70, 74, 74,
respectively). In the BID treatment groups, 212 patients
received either 2 % tofacitinib, 1 % tofacitinib, or vehicle
(n = 71, 70, 71, respectively). Baseline demographics were
generally similar across the treatment groups, with the
exception of geographical distribution between the
dosing regimens (Table 1).Efficacy
Only those treatment groups and time points that were
statistically significant are described within the text.Primary endpoints
At Week 8 only, significantly more patients receiving
2 % tofacitinib QD and 2 % tofacitinib BID achieved
a PGA-C response of clear or almost clear and ≥2 grade
improvement from baseline compared with the corre-
sponding vehicle. Response rate was 18.6 % and 8.1 %
for 2 % tofacitinib QD and vehicle QD, respectively,
and 22.5 % and 11.3 % for 2 % tofacitinib BID and ve-
hicle BID, respectively. The difference (80 % CI) be-
tween response to active treatment and vehicle was
10.8 % (3.1, 18.5) and 11.0 % (3.8, 18.2) for 2 % tofacitinib
BID and QD administration, respectively (Fig. 2a–b). At
Week 12, no statistically significant differences versus
vehicle were seen for 2 % or 1 % tofacitinib by either
dosing regimen (Fig. 2a–b).Fig. 1 Patient disposition. Note that the 714 subjects includes subjects with
that met the mild to moderate psoriasis eligibility criteria. Following databa
did not have any record of study drug dosing and were assessed in th
these subjects were excluded from all analyses. BID twice daily, QD onSecondary endpoints
The proportion of patients achieving a PGA-C response
of clear or almost clear was significantly greater for the
2 % tofacitinib QD (35.9 %), 2 % tofacitinib BID (41.8 %)
and 1 % tofacitinib QD (23.4 %) treatment groups com-
pared with vehicle (QD 13.8 %, BID 25.2 %) at Week 8,
and for the 2 % tofacitinib BID (39.7 %) treatment group
compared with vehicle (27.3 %) at Week 12 (Table 2).
At Week 8 and Week 12, significantly more patients
receiving 2 % tofacitinib QD (17.9 % and 23.0 %, respect-
ively) achieved a PASI75 response vs vehicle (8.3 % and
8.8 %, respectively) (Table 2). The percent change from
baseline in PASI was also significantly greater for the
2 % tofacitinib QD treatment group compared with
vehicle at Week 8 and Week 12 (Table 2); the differences
(80 % CI) vs corresponding vehicle were −9.2 % (−17.1,
−1.4) and −12.3 % (−21.8, −2.8) at Weeks 8 and 12,
respectively. The percent change from baseline in BSA
was also significantly greater for the 2 % tofacitinib QD
treatment group compared with vehicle at Week 12
(Table 2); the difference (80 % CI) vs corresponding
vehicle was −20.0 % (−31.4, −8.7).Patient-reported outcomes
2 % and 1 % tofacitinib BID significantly reduced prur-
itus compared with vehicle BID as early as Day 2 (the
day following the initial dose); these improvements were
sustained through Day 14 (Fig. 3a). Numerically greater
improvements in ISI were also seen in the 2 % and 1 %
tofacitinib QD treatment groups compared with vehicle
QD; these improvements were statistically significant for
2 % tofacitinib QD on Days 3–14 (Fig. 3b). Significant
improvements in pruritus were maintained for 2 % BID,
1 % BID, and 2 % QD from Week 2 through Week 12
(except Week 8 and 12 for 2 % QD).mild, moderate, and severe psoriasis; subjects randomized are those
se release, it was discovered that five subjects were randomized, but
e clinical database as non-treated subjects; as a consequence,
ce daily
Table 1 Baseline patient demographics and disease characteristics
2 % tofacitinib BID 1 % tofacitinib BID Vehicle BID 2 % tofacitinib QD 1 % tofacitinib QD Vehicle QD
N = 71 N = 70 N = 71 N = 70 N = 74 N = 74
Age (years)
Mean (SD) 47.6 (15.6) 50.4 (14.5) 48.8 (15.0) 50.7 (13.2) 47.8 (14.0) 48.9 (13.9)
Range 18.0–74.0 18.0–77.0 21.0–84.0 21.0–77.0 20.0–85.0 20.0–74.0
Male (%) 60.6 67.1 57.7 52.9 67.6 56.8
BMI (kg/m2)
Mean (SD) 31.8 (7.9) 29.6 (5.6) 30.2 (8.3) 28.9 (7.8) 31.0 (7.2) 31.1 (6.5)
Range 17.2–58.4 19.2–51.4 17.0–79.8 16.4–68.6 17.6–50.4 20.6–47.4
Race (%)
White 93.0 85.7 94.4 90.0 91.9 97.3
Black 1.4 4.3 1.4 1.4 2.7 2.7
Asian 4.2 7.1 2.8 5.7 2.7 0.0
Other 1.4 2.9 1.4 2.9 2.7 0.0
Geographical region (%)
Canada 15.5 30.0 26.8 27.1 23.0 33.8
Denmark 1.4 1.4 0.0 1.4 1.4 1.4
Poland 14.1 12.9 15.5 32.9 39.2 28.4
United States 69.0 55.7 57.7 38.6 36.5 36.5
PGA-C (%)
Mild 28.2 30.0 29.6 32.9 27.0 27.0
Moderate 71.8 70.0 70.4 67.1 73.0 73.0
PASI score
Mean (SD) 9.5 (5.1) 8.5 (3.3) 8.5 (3.6) 9.9 (4.1) 10.1 (4.4) 9.6 (3.8)
Range 2.4–29.0 3.0–18.0 2.4–18.0 2.0–19.8 2.8–19.8 3.2–17.1
BSA (%)
Mean (SD) 7.6 (4.6) 6.4 (3.8) 6.5 (4.1) 7.8 (4.3) 8.4 (4.9) 8.0 (4.5)
Range 2.0–19.0 1.5–17.0 2.0–20.0 2.0–19.0 2.4–20.0 2.0–19.0
ISI scorea
Mean (SD) 5.8 (2.6) 5.3 (2.4) 5.4 (2.6) 6.0 (2.7) 5.7 (2.9) 5.4 (3.0)
Range 0.0–10.0 1.0–10.0 0.0–10.0 0.0–10.0 0.0–10.0 0.0–10.0
DLQI
Mean (SD) 10.6 (5.9) 8.6 (5.5) 9.3 (6.0) 12.2 (7.4) 10.9 (7.0) 10.2 (6.5)
Range 0.0–25.0 1.0–25.0 1.0–24.0 1.0–29.0 1.0–29.0 0.0–26.0
aTwo patients were missing baseline ISI scores (1 in 2 % tofacitinib QD; 1 in 1 % tofacitinib BID)
BID twice daily, BMI body mass index, BSA body surface area, DLQI Dermatology Life Quality Index, ISI Itch Severity Item, PASI Psoriasis Area and Severity Index,
PGA-C Calculated Physician’s Global Assessment, QD once daily, SD standard deviation
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improved DLQI more than their respective vehicles
(Additional file 1: Figure S1). At Week 12, 2 % tofacitinib
QD and 1 % tofacitinib QD significantly improved DLQI
more than the vehicle (Additional file 1: Figure S1).
Safety
All adverse events
Overall, 44.2 % of patients experienced treatment-
emergent AEs, most of which were mild or moderate inseverity (Table 3). The highest incidence of treatment-
emergent AEs was in the vehicle QD group, with 54.1 %
of patients in this group reporting one or more
treatment-emergent AE. The most frequently reported
AEs by Medical Dictionary for Regulatory Activities
(MedDRA; version 17.1) preferred term were nasophar-
yngitis (6.7 %), upper respiratory tract infection (4.9 %),
and psoriasis (4.9 %).
A total of 11 SAEs were experienced by 10 (2.3 %)
patients. No SAEs were reported in the 2 % tofacitinib
Fig. 2 PGA-C response of clear (0)/almost clear (1) and ≥2 grade improvement at Week 16. *Lower limit 80 % CI of difference tofacitinib versus
vehicle >0. Proportion (SE) of patients achieving a PGA-C response of clear (0) or almost clear (1) and ≥2 grade improvement from
baseline through to Week 16 for patients applying 2 % tofacitinib, 1 % tofacitinib, or vehicle, once daily (a) or twice daily (b). Patients
who were discontinued or with missing values were considered non-responders. BID twice daily, BL baseline, CI confidence interval, PGA-C
Calculated Physician’s Global Assessment, PGA-Cm Calculated Physician’s Global Assessment of patients with mild to moderate plaque
psoriasis at baseline, QD once daily, SE standard error, tofa tofacitinib
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patients in the 1 % tofacitinib BID group, in two patients
in each of the 1 % tofacitinib QD and vehicle BID
groups, and in one patient in the vehicle QD group
(Additional file 1: Table S1). No SAEs were assessed by
the investigator as treatment-related, with the exception
of one SAE of psoriatic arthropathy in the vehicle BID
treatment group.
Overall, 21 (4.9 %) patients discontinued from the study
due to AEs, most commonly psoriasis, which was reported
by six (1.4 %) patients. Seven patients discontinued due to
AEs in the vehicle QD group, six with 2 % tofacitinib QD,four with vehicle BID, three with 1 % tofacitinib QD, and
one with 1 % tofacitinib BID (patient was discontinued
from the study due to a fatal myocardial infarction as
described below).
One death (due to myocardial infarction) occurred in
a 53-year-old white male receiving 1 % tofacitinib BID.
His final application of tofacitinib ointment was on
Study Day 74 and he died on Study Day 86. Relevant
medical history included prior myocardial infarction and
stent placement, dyslipidemia, hypertension, and 18-year
history of tobacco use. The event was considered unre-
lated to study treatment by the investigator.
Table 2 Secondary efficacy endpoints
Endpoint Week 2 % tofacitinib BID 1 % tofacitinib BID Vehicle BID 2 % tofacitinib QD 1 % tofacitinib QD Vehicle QD
PGA-C, clear (0)
or almost clear (1)
Responders, % (n/N)




















































































aDifference active – vehicle; bmeets specification for statistical significance
PASI excluded the scalp, palms, and soles from the assessment/scoring, even if these areas were being treated with study drug. BSA excluded the head, neck,
palms, and soles, even if these areas were being treated with study drug
PGA-C and PASI75 responses were analyzed using a Generalized Mixed Model for Repeated Measures without imputation for missing values; percent changes
from baseline in PASI and BSA were analyzed using a Mixed Model for Repeated Measures without imputation for missing values; QD and BID data were
analyzed separately
BID twice daily, BSA body surface area, CI confidence interval, LSM least squares mean, PASI Psoriasis Area and Severity Index, PGA-C Calculated Physician’s Global
Assessment, QD once daily
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Application site AEs were reported in 35 of the
190 (18.4 %) patients who experienced treatment-
emergent AEs (8.1 % of total study population); no ap-
plication site AEs were serious (Table 3). The highest
incidence was in the vehicle QD group (Table 3). The
most frequently reported application site AEs by Med-
DRA preferred term were psoriasis (reported by 18
[4.2 %] patients), pruritus (9 [2.1 %]), and application
site pain (3 [0.7 %]).
A total of 12 (2.8 %) patients discontinued the study
due to application site AEs; seven were from the vehicle
QD group, three from the 2 % tofacitinib QD group, and
one from each of the vehicle BID and 1 % tofacitinib
QD groups. The most common application site AE lead-
ing to discontinuation was psoriasis, which was reported
by six (1.4 %) patients.
Laboratory assessments
Thirteen patients met the criteria for laboratory safety
monitoring (Table 4); no patients met the laboratory
monitoring criteria for discontinuation.
Pharmacokinetics
Tofacitinib concentrations were above the lower limit of
quantification of 0.01 ng/mL in most plasma samples,
with the largest percentage of samples in the concentra-
tion range of 0.1 to <1.0 ng/mL (Additional file 1: Table
S2). There was a general trend toward higher concentra-
tions with higher dose strength (2 % vs 1 %) but no cleardifference between the dosing regimens (BID vs QD).
Across tofacitinib treatment groups, 83.3 %–97.4 % of
plasma tofacitinib concentrations were <1.0 ng/mL. The
maximum observed plasma concentration of 9.7 ng/mL
occurred at Week 12 in the 2 % tofacitinib QD group.
Based on the post-dose PK obtained in a limited number
of patients, the PK had a flat profile with limited fluctu-
ation in concentrations between doses, as would be
expected after topical application. Total exposure based
on area under the plasma concentration time profile
from time zero to the time tau (AUCtau) in patients with
post-dose PK was higher with the higher dose strength,
while the relationship between exposure and dose regi-
men was not clear (Additional file 1: Table S3).
Discussion
Partial inhibition of JAK signaling by tofacitinib results
in a multi-tiered intervention in the cycle of psoriasis
pathogenesis, with direct impact on dysregulated kerati-
nocytes, reduction in inflammatory infiltrate and, ultim-
ately, normalization of the interleukin (IL)-23/Th17 axis
[23]. Oral tofacitinib is effective in patients with moder-
ate to severe plaque psoriasis [14–16], and evidence of
efficacy has been seen in the patient with mild to moder-
ate plaque psoriasis with a 2 % topical formulation of
tofacitinib applied BID [17].
The current study assessed the efficacy and safety of
two dose strengths (2 % and 1 %) of tofacitinib ointment
applied either QD or BID in adult patients with mild to
moderate plaque psoriasis. Greater efficacy response was
Fig. 3 Change from baseline in Itch Severity Item score through Week 2. Least squares mean (SE) change from baseline in Itch Severity Item
score through Week 2 for patients applying 2 % tofacitinib, 1 % tofacitinib, or vehicle, once daily (a) or twice daily (b). Changes from baseline in
ISI were analyzed using a Mixed Model for Repeated Measures without imputation for missing values; QD and BID data were analyzed separately.
BID twice daily, ISI Itch Severity Item, LSM least squares mean, PGA-Cm Calculated Physician’s Global Assessment of patients with mild to
moderate plaque psoriasis at baseline, QD once daily, SE standard error, tofa tofacitinib
Table 3 Summary of adverse events, patients discontinued due to adverse events and deaths
2 % tofacitinib BID 1 % tofacitinib BID Vehicle
BID
2 % tofacitinib QD 1 % tofacitinib QD Vehicle
QD
N = 71 N = 70 N = 71 N = 70 N = 74 N = 74
Number of AEs 47 51 54 66 65 62
Patients with treatment-emergent AEs, n (%) 30 (42.3) 30 (42.9) 28 (39.4) 34 (48.6) 28 (37.8) 40 (54.1)
Patients with application site AEs, n (%) 4 (5.6) 0 (0.0) 4 (5.6) 8 (11.4) 7 (9.5) 12 (16.2)
Patients with SAEs, n (%) 0 (0.0) 5 (7.1) 2 (2.8) 0 (0.0) 2 (2.7) 1 (1.4)
Patients discontinued due to AEs, n (%) 0 (0.0) 1 (1.4)a 4 (5.6) 6 (8.6) 3 (4.1) 7 (9.5)
Deaths, n (%) 0 (0.0) 1 (1.4)a 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
aPatient had an AE of myocardial infarction and subsequently died; the patient is counted as a discontinuation due to AE and as a death
Categories of adverse events experienced include treatment-emergent, application site and serious adverse events
AE adverse event, BID twice daily, QD once daily, SAE serious adverse event
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Table 4 Patients with laboratory values meeting pre-specified protocol criteria* for safety monitoring
Criterion, % (n/N) 2 % tofacitinib BID 1 % tofacitinib BID Vehicle
BID
2 % tofacitinib QD 1 % tofacitinib QD Vehicle
QD
Any criterion 2.9 (2/70) 2.9 (2/70) 1.4 (1/69) 5.8 (4/69) 4.1 (3/73) 1.4 (1/73)
Hemoglobina 1.5 (1/68) 0.0 (0/70) 0.0 (0/69) 0.0 (0/67) 4.1 (3/73) 1.4 (1/72)
Neutrophil countb 0.0 (0/68) 0.0 (0/69) 0.0 (0/69) 1.5 (1/67) 0.0 (0/73) 0.0 (0/72)
Lymphocyte countc 0.0 (0/68) 0.0 (0/70) 0.0 (0/69) 0.0 (0/67) 0.0 (0/73) 0.0 (0/71)
Platelet countd 0.0 (0/68) 0.0 (0/69) 0.0 (0/69) 0.0 (0/67) 0.0 (0/73) 0.0 (0/72)
Serum creatininee 1.4 (1/69) 0.0 (0/70) 0.0 (0/69) 1.5 (1/67) 0.0 (0/73) 0.0 (0/72)
AST/ALTf 0.0 (0/69) 2.9 (2/70) 1.4 (1/69) 1.5 (1/67) 0.0 (0/73) 0.0 (0/72)
CPKg 0.0 (0/69) 0.0 (0/70) 1.4 (1/69) 3.0 (2/67) 0.0 (0/73) 0.0 (0/72)
*aAny hemoglobin value >2 g/dL (>20 g/L) below baseline; bAbsolute neutrophil count <1.2 × 109/L (<1200/mm3); cAbsolute lymphocyte count <0.5 × 109/L
(<500 lymphocytes/mm3); dPlatelet count <100 × 109/L (<100,000/mm3); eSerum creatinine increase >50 % over the average of screening and baseline values OR
absolute increase in serum creatinine >0.5 mg/dL (>44.2 μmol/L) over the average of screening and baseline values; fAny AST and/or ALT elevation ≥3 times the
ULN, regardless of the total bilirubin; gAny CPK >5xULN
ALT alanine aminotransferase, AST aspartate aminotransferase, BID twice daily, CPK creatine phosphokinase, QD once daily, ULN upper limit of normal
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nib, and overall no clear distinction in efficacy was seen
between BID and QD dosing.
Greater efficacy of tofacitinib compared with vehicle
was seen for more primary and secondary efficacy end-
points at Week 8 than Week 12. While it appeared that
the PGA-C response of clear or almost clear and ≥2 grade
improvement from baseline plateaued after Week 8, the
vehicle treatment group PGA-C responses continued to
improve after Week 8, thereby decreasing the difference
between tofacitinib and vehicle at Week 12. Explanation
for the increase in vehicle responses between Week 8 and
Week 12 was not evident after thorough review of the
study data for potential contributing factors, although it is
possible this could be related to the small sample size of
the study.
Patients were required to achieve a ≥2 grade improve-
ment from baseline in PGA-C in addition to having a
PGA-C score of clear or almost clear to be considered a
responder for the primary efficacy endpoint. This is a
much more challenging threshold than the achievement
of a PGA-C score of clear or almost clear alone, when a
patient need only change from mild (2) to almost clear
(1) to be considered a responder. This more stringent
criterion is used, as a change from the low end of the
mild range to the high end of the almost clear range
may not represent a clinically meaningful change.
The clinical significance of objective changes in disease
severity were confirmed by the improvement in patient-
reported measures. Improvements in health-related
quality of life, as indicated by DLQI, reflected the
changes seen in PGA-C and PASI. Greater improve-
ments in pruritus were seen compared with vehicle in
both tofacitinib BID dosing groups from Day 2 of dosing
and for 2 % tofacitinib QD from Day 3. The improve-
ments in pruritus from baseline were likely clinically
meaningful (defined as a LSM decrease from baseline inISI of 2 points based on analyses conducted with oral
tofacitinib therapy for psoriasis) [19] and were seen with
1 % tofacitinib BID from Day 4 through Day 14, with 2 %
tofacitinib BID from Day 5 through Day 14, and with 2 %
tofacitinib QD from Day 8 through Day 14 (Fig. 3a).
Previous studies have shown oral tofacitinib improved
patient-reported pruritus in moderate to severe psoriasis
[19, 24, 25]. This is a direct effect, independent from
improvements in clinician-reported signs of psoriasis
severity [24], with a statistically significant improvement
occurring as early as the second day of dosing [26]. Top-
ical tofacitinib also improves pruritus in patients with
atopic dermatitis [27].
A very rapid reduction in ISI was seen on initiation of
treatment, with a significant reduction in pruritus with
both 2 % and 1 % tofacitinib BID compared with vehicle
BID as early as the day following the initial dose.
Although pruritus is a common feature of psoriasis, the
underlying pathogenesis is not understood. Impaired
innervation and neuropeptide imbalance in psoriatic
skin may be involved; other potential mechanisms
include increased expression of IL-2, the opioid system,
prostanoids, IL-31, serotonin, proteases and/or vascular
abnormalities [28, 29]. Tofacitinib inhibition of JAK may
suppress pruritus by blocking signaling via IL-31 [30, 31]
and reducing expression of IL-2 [32]. As neuropeptides
have a role in the pathogenesis of both psoriasis and
pruritus, increased expression of substance P receptor,
high-affinity nerve growth factor receptor or calcitonin
gene-related peptide receptor may be involved [29].
Overall, topically administered tofacitinib had an
acceptable safety profile, with no clinically meaningful
differences in the incidence of AEs or SAEs between
tofacitinib and vehicle treatment groups. The incidence
of AEs coding to the MedDRA Infections and Infesta-
tions system organ class was higher in patients receiving
vehicle than patients receiving tofacitinib. None of the
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corticosteroids were observed.
The range of observed plasma concentrations of tofa-
citinib from the PK analysis showed significant overlap
between the dose strengths and regimens. Both AUCtau
and maximum observed plasma concentration were
higher in patients with QD administration than with
BID administration, which was not expected. In addition
to dose strength and regimen, PK exposure is likely re-
lated to the treatment BSA and/or ointment application
rate and this may be contributing to the lack of clear dif-
ferentiation between the regimens.
In Phase 3 studies of oral tofacitinib in patients with
moderate to severe psoriasis, serious infections and her-
pes zoster infections were associated with tofacitinib
treatment [14, 15]. Based on an exposure-response ana-
lysis of oral tofacitinib psoriasis data, an average tofaciti-
nib exposure of 12.4 ng/mL was not associated with
increased incidence rates of serious infections and her-
pes zoster infections when compared to patients treated
with placebo (unpublished observations). In the current
study, more than 83 % of tofacitinib levels measured in
plasma from patients in all active treatment groups were
<1.0 ng/mL, which represents a >12-fold margin to the
exposure levels for oral tofacitinib with no increased
incidence rates for serious and herpes zoster infections
relative to placebo observed in the oral tofacitinib Phase 3
psoriasis program.
Study limitations
To form the basis for further clinical development, this
Phase 2b estimation study used the 2-sided 80 % confi-
dence interval as the pre-specified confidence level per
study protocol, whereas in a Phase 3 trial the more
rigorous 95 % confidence interval or 0.05 significance
level would be used. The stringent eligibility criteria of a
Phase 2b clinical study generally exclude some patients
who may have been considered for topical treatment
outside of the clinical trial environment. The numbers of
patients included in the study (~70 per treatment group)
is a relatively small sample size. Caution is therefore
needed in extrapolating findings to real-world clinical
practice. No active comparator to tofacitinib was
included so efficacy was not assessed relative to another
agent with a known therapeutic effect in psoriasis. No
formal statistical comparison was made between QD
and BID application, as study sites were assigned to ei-
ther QD or BID regimens, not both. As such, the dosing
regimens essentially represent two separate sub-studies.
Conclusions
This small Phase 2b study demonstrated that topical
treatment with the JAK inhibitor tofacitinib in an oint-
ment formulation provided improvement in the clinicalsigns of psoriasis for patients with mild to moderate
chronic plaque psoriasis. Based on the prespecified pri-
mary efficacy endpoint, which assesses clinical signs, tofa-
citinib as a 2 % ointment formulation applied either QD
or BID showed significantly greater efficacy compared
with vehicle at Week 8, but not at Week 12, and not as a
1 % ointment formulation. Acceptable safety and local tol-
erability profiles for both QD and BID dosing regimens
were observed during 12 weeks of treatment.
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